One-Dose hope for blistering skin disease?
NCT ID NCT00525616
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a single cycle of rituximab can control bullous pemphigoid, a severe blistering skin condition. Eighteen adults with steroid-dependent or relapsing disease were enrolled. Researchers checked disease control weekly for a month and then monthly for two years, while also monitoring side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BULLOUS PEMPHIGOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rouen University Hospital, Direction de la Recherche et de l'Innovation,
Rouen, 76031, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Study reveals bone risks from common skin treatment
- Scientists probe hidden clot risks in autoimmune skin disorders
- New study tests easier treatment for blistering skin disease
- New antibody treatment offers hope for rare blistering skin disease
- Researchers track blistering skin disease to pave way for better treatments
- New antibody shows promise for blistering skin disease